HIV/AIDS

The payload identifies HIV/AIDS as a viral condition, formally named Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome, and maps it to ICD-10 B20-B24 and ICD-11 1C62. In the supplied material, HIV/AIDS is discussed as a condition whose mortality and long-term impact have been altered by antiretroviral therapy, rather than as a newly emerging infection ^[1]. Source-backed detail on virologic characterization beyond the disease name itself is not yet available in the provided snippets ^[1].

The snippets state that antiretroviral therapy has markedly increased life expectancy in people with HIV, and that AIDS has become a largely preventable complication of HIV infection ^[1]. They also indicate that AIDS occurs mainly in the setting of delayed diagnosis or delayed treatment initiation ^[1]. Beyond this, the provided sources do not give a source-backed description of the symptom complex, organ involvement, stage-specific manifestations, or complication spectrum for HIV/AIDS, so those details are not added here. The available material does note that long-term medication effects and conditions associated with accelerated aging in HIV infection are emerging clinical challenges ^[1].

No population-level incidence, prevalence, geographic distribution, or outbreak pattern for HIV/AIDS is provided in the supplied snippets. The only epidemiologic context available is indirect: one source uses HIV/AIDS as a comparator for the global burden of tuberculosis, and another notes that histoplasmosis poses particular challenges in people living with HIV/AIDS ^[2][3]. The available material therefore supports HIV/AIDS as an important background condition in broader infectious-disease surveillance, but does not provide source-backed burden estimates for HIV/AIDS itself ^[2][3].

Source-backed detail on the transmission mechanism of HIV/AIDS is not yet available in the provided snippets. The supplied sources discuss the disease in relation to diagnosis, therapy, and complication prevention, but do not describe routes of acquisition or exposure settings ^[1]. No additional transmission claims are made here beyond what is explicitly supported.

The provided snippets identify people living with HIV/AIDS as a clinically important immunocompromised group, and one review specifically names organ transplant recipients alongside them as populations at elevated risk for histoplasmosis ^[3]. Another source suggests that AIDS occurs especially when diagnosis or treatment is delayed, implying greater risk of advanced disease among persons not reached early by care ^[1]. Beyond these source-backed statements, additional risk-group detail is not yet available in the supplied material ^[1][3].

The clearest prevention-related statement in the supplied material is that AIDS is described as a largely preventable complication of HIV infection, particularly when diagnosis is not delayed and therapy is not started too late ^[1]. The histoplasmosis review also identifies people living with HIV/AIDS as a group in whom fungal disease prevention and surveillance warrant attention, but it does not specify HIV/AIDS prevention measures themselves ^[3]. Source-backed detail on particular public-health interventions, vaccination, prophylaxis, or behavioral prevention is not yet available in the provided snippets ^[1][3].

For surveillance purposes, the supplied sources suggest reading HIV/AIDS as a chronic infection-disease complex whose observed AIDS burden is influenced by the timeliness of diagnosis and treatment initiation ^[1]. The presence of AIDS in a case series or program report may therefore signal gaps in earlier detection or linkage to care, rather than simply underlying infection frequency ^[1]. The surrounding literature also uses HIV/AIDS as a marker of immunocompromised status in studies of opportunistic infections such as histoplasmosis, which may be relevant when interpreting co-infection reports ^[3].

1. 1 HIV/Aids. Public Health Forum. 2010. doi: 10.1016/j.phf.2009.12.013. DOI: https://doi.org/10.1016/j.phf.2009.12.013
2. 2 Dao A et al. Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list. Med Mycol. 2024 Jun 27. PMID: 38935903. doi: 10.1093/mmy/myae039. PubMed: https://pubmed.ncbi.nlm.nih.gov/38935903/
3. 3 Natarajan A et al. A systemic review on tuberculosis. Indian J Tuberc. 2020 Jul. PMID: 32825856. doi: 10.1016/j.ijtb.2020.02.005. PubMed: https://pubmed.ncbi.nlm.nih.gov/32825856/
4. 4 Holmes KK et al. Drug-Resistant Infections. 2017 Nov 3. PMID: 30212094. doi: 10.1596/978-1-4648-0524-0_ch18. PubMed: https://pubmed.ncbi.nlm.nih.gov/30212094/
5. 5 HIV/AIDS and HIV/AIDS-Related Terminology. Scholarly DOI record. 2013. doi: 10.4324/9781315863191. DOI: https://doi.org/10.4324/9781315863191
6. 6 HIV/AIDS. Gastroenterology and Hepatology. 2008. doi: 10.1016/b978-0-7295-3775-9.50022-6. DOI: https://doi.org/10.1016/b978-0-7295-3775-9.50022-6

ICD-10

B20-B24

ICD-11

1C62

Total cases

893K

Total deaths

267K

Peak month

2018-12

Coverage

3 reporting countries · 2013-01-01 → 2026-06-20